{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:57:35Z","timestamp":1784257055132,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Biliary tract cancers (BTCs) are rare and lethal cancers, with a 5-year survival inferior to 20%(1\u20133). The only potential curative treatment is surgical resection. However, despite complex surgical procedures that have a remarkable risk of postoperative morbidity and mortality, the 5-year survival rate after radical surgery (R0) is 20\u201340% and recurrence rates are up to\u2009~\u200975%(4\u20136). Up to\u2009~\u200940% of patients relapse within 12\u00a0months after resection, and half of these patient will recur systemically(4\u20136). There is no standard of care for neoadjuvant chemotherapy (NAC) in resectable BTC, but retrospective reports suggest its potential benefit (7, 8).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PURITY is a no-profit, multicentre, randomized phase II\/III trial aimed at evaluating the efficacy of the combination of gemcitabine, cisplatin and nabpaclitaxel (GAP) as neoadjuvant treatment in patients with resectable BTC at high risk for recurrence. Primary objective of this study is to evaluate the efficacy of neoadjuvant GAP followed by surgery as compared to upfront surgery, in terms of 12-month progression-free survival for the phase II part and of progression free survival (PFS) for the phase III study.<\/jats:p>\n                <jats:p>Key Secondary objectives are event free survival (EFS), relapse-free survival, (RFS), overall survival (OS), R0\/R1\/R2 resection rate, quality of life (QoL), overall response rate (ORR), resectability. Safety analyses will include toxicity rate and perioperative morbidity and mortality rate.<\/jats:p>\n                <jats:p>Exploratory studies including Next-Generation Sequencing (NGS) in archival tumor tissues and longitudinal ctDNA analysis are planned to identify potential biomarkers of primary resistance and prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Considering the poor prognosis of resected BTC experiencing early tumor recurrence and the negative prognostic impact of R1\/R2 resections, PURITY study is based on the rationale that NAC may improve R0 resection rates and ultimately patients\u2019 outcomes. Furthermore, NAC should allow early eradication of microscopic distant metastases, undetectable by imaging but already present at the time of diagnosis and avoid mortality and morbidity associated with resection for patients with rapid progression or worsening general condition during neoadjuvant therapy. The randomized PURITY study will evaluate whether patients affected by BTC at high risk from recurrence benefit from a neoadjuvant therapy with GAP regimen as compared to immediate surgery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>PURITY is registered at ClinicalTrials.gov (NCT06037980) and EuCT(2023\u2013503295-25\u201300).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12225-6","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T14:02:13Z","timestamp":1712584933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A phase II\/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study"],"prefix":"10.1186","volume":"24","author":[{"given":"Monica","family":"Niger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Nichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pircher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Pressiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Casadei","family":"Gardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sperti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Melisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Mosconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Longarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Arcangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Corallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Delliponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tamberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilario Giovanni","family":"Rapposelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Salati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Baili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silva","family":"Ljevar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sottotetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Martinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Droz Dit","family":"Busset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Sposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Di Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mazzaferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"issue":"1","key":"12225_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"12225_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10272","key":"12225_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344.","journal-title":"Lancet"},{"issue":"7","key":"12225_CR4","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/bjs.10676","volume":"105","author":"XF Zhang","year":"2018","unstructured":"Zhang XF, Beal EW, Bagante F, Chakedis J, Weiss M, Popescu I, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018;105(7):848\u201356.","journal-title":"Br J Surg"},{"issue":"8","key":"12225_CR5","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1245\/s10434-021-09811-4","volume":"28","author":"K Sahara","year":"2021","unstructured":"Sahara K, Tsilimigras DI, Toyoda J, Miyake K, Ethun CG, Maithel SK, et al. Defining the risk of early recurrence following curative-intent resection for distal cholangiocarcinoma. Ann Surg Oncol. 2021;28(8):4205\u201313.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"12225_CR6","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1245\/s10434-021-09626-3","volume":"28","author":"EA Vega","year":"2021","unstructured":"Vega EA, Newhook TE, Kawaguchi Y, Qiao W, De Bellis M, Okuno M, et al. Conditional recurrence-free survival after oncologic extended resection for gallbladder cancer: an international multicenter analysis. Ann Surg Oncol. 2021;28(5):2675\u201382.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"12225_CR7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ejso.2019.03.023","volume":"45","author":"S Yadav","year":"2019","unstructured":"Yadav S, Xie H, Bin-Riaz I, Sharma P, Durani U, Goyal G, et al. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched analysis. Eur J Surg Oncol. 2019;45(8):1432\u20138.","journal-title":"Eur J Surg Oncol"},{"key":"12225_CR8","doi-asserted-by":"publisher","unstructured":"Utuama O, Permuth JB, Dagne G, Sanchez-Anguiano A, Alman A, Kumar A, et al. Neoadjuvant chemotherapy for intrahepatic cholangiocarcinoma: a propensity score survival analysis supporting use in patients with high-risk disease. Ann Surg Oncol. 2021;28(4):1939-49. https:\/\/doi.org\/10.1245\/s10434-020-09478-3.","DOI":"10.1245\/s10434-020-09478-3"},{"key":"12225_CR9","doi-asserted-by":"publisher","unstructured":"Sahara K, Tsilimigras DI, Toyoda J, Miyake K, Ethun CG, Maithel SK, et al. Defining the risk of early recurrence following curative-intent resection for distal cholangiocarcinoma. Ann Surg Oncol. 2021;28(8):4205-13.\u00a0https:\/\/doi.org\/10.1245\/s10434-021-09811-4.","DOI":"10.1245\/s10434-021-09811-4"},{"issue":"18","key":"12225_CR10","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1200\/JCO.21.02568","volume":"40","author":"J Bridgewater","year":"2022","unstructured":"Bridgewater J, Fletcher P, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Long-term outcomes and exploratory analyses of the randomized Phase III BILCAP study. J Clin Oncol. 2022;40(18):2048\u201357.","journal-title":"J Clin Oncol"},{"key":"12225_CR11","unstructured":"Brustia R, Langella S, Kawai T, Fonseca GM, Schielke A, Colli F, et al. Preoperative risk score for prediction of long-term outcomes after hepatectomy for intrahepatic cholangiocarcinoma: Report of a collaborative, international-based, external validation study. Eur J Surg Oncol. 2020;46(4 Pt A):560\u201371."},{"issue":"9","key":"12225_CR12","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/jamasurg.2020.1973","volume":"155","author":"DI Tsilimigras","year":"2020","unstructured":"Tsilimigras DI, Sahara K, Wu L, Moris D, Bagante F, Guglielmi A, et al. Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches. JAMA Surg. 2020;155(9):823\u201331.","journal-title":"JAMA Surg"},{"key":"12225_CR13","doi-asserted-by":"publisher","unstructured":"Hassan H, Chakrabarti S, Zemla T, Yin J, Wookey V, Prasai K, et al. Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection. Eur J Surg Oncol. 2023;49(11):106994. https:\/\/doi.org\/10.1016\/j.ejso.2023.106994.","DOI":"10.1016\/j.ejso.2023.106994"},{"key":"12225_CR14","doi-asserted-by":"publisher","unstructured":"Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;1;5(6):824-30. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0270.","DOI":"10.1001\/jamaoncol.2019.0270"},{"key":"12225_CR15","doi-asserted-by":"crossref","unstructured":"Shroff RT, Guthrie KA, Scott AJ, Borad MJ, Goff LW, Matin K, et al. SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J Clin Oncol. 2023;41(4_suppl):LBA490-LBA.","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA490"},{"key":"12225_CR16","doi-asserted-by":"crossref","unstructured":"Maithel SK, Javle MM, Mahipal A, Lin BS-L, Akce M, Switchenko JM, et al. NEO-GAP: A phase II single-arm prospective feasibility study of neoadjuvant gemcitabine\/cisplatin\/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma. J Clin Oncol. 2022;40(16_suppl):4097.","DOI":"10.1200\/JCO.2022.40.16_suppl.4097"},{"issue":"2","key":"12225_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.surg.2022.09.028","volume":"173","author":"SH Choi","year":"2023","unstructured":"Choi SH, Kang I, Lee SH, Kang B, Cheon J, Kim DJ, et al. Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma. Surgery. 2023;173(2):280\u20138.","journal-title":"Surgery"},{"key":"12225_CR18","doi-asserted-by":"publisher","unstructured":"Maithel SK, Keilson JM, Cao HST, Rupji M, Mahipal A, Lin BS, et al. NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2023;30(11):6558-66. https:\/\/doi.org\/10.1245\/s10434-023-13809-5.","DOI":"10.1245\/s10434-023-13809-5"},{"issue":"5","key":"12225_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663\u201373.","journal-title":"Lancet Oncol"}],"updated-by":[{"DOI":"10.1186\/s12885-024-12328-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12225-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12225-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12225-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T08:02:33Z","timestamp":1714982553000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12225-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12225"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12225-6","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12885-024-12328-0","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-024-12328-0","URL":"https:\/\/doi.org\/10.1186\/s12885-024-12328-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was registered on 16\/03\/2023 at EuCT database (2023-503295-25-00) and on 07 Sep 2023 at Clinicaltrials.gov (NCT06037980) and it is currently ongoing.The trial was submitted to CTIS and approved by the Ethics Committee \u201cCET Comitato Etico Regione Toscana \u2013 Area Vasta Sud Est\u201d.All study participants will provide their written informed consent after careful explanation by their treating investigators.This study will be conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki. The study will comply with the requirements of the ICH E2A guideline.Sponsor\u2019s sample Informed Consent Form will be provided to each site. Regarding exploratory analyses, the investigator or authorized designee will explain to each patient the objectives of the exploratory research. Patients will be told that they are free to refuse to participate and may withdraw their specimens at any time and for any reason. All relevant changes to study procedures or new information will be communicated to all relevant parties (investigators, IRBs, trial participants, trial registries, journals, regulators) and patients will be re-consented to the most current version of the Consent Forms (or to a significant new information\/findings addendum in accordance with applicable laws and IRB\/EC policy).The Sponsor maintains confidentiality standards by coding each patient enrolled in the study through assignment of a unique patient identification number. This means that patient names are not included in any of the study data sets. Patient medical information obtained by this study is confidential and may only be disclosed to third parties as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law. Data generated by this study must be available for inspection upon request by representatives of the national and local health authorities, Sponsor\u2019s monitors, representatives, and collaborators, and the IRB\/EC for each study site, as appropriate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MN: Travel expenses from AstraZeneca, speaker honorarium from Accademia della Medicina and Incyte; honoraria from Sandoz, Medpoint SRL, Incyte and Servier for editorial collaboration. Consultant honoraria from EMD Serono, Basilea Pharmaceutica, Incyte, MSD Italia, Servier, Astrazeneca and TaihoLR: reports consulting fees from AstraZeneca, Basilea, Bayer, BMS, Eisai, Elevar Therapeutics, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Jazz Pharmaceuticals, Lilly, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; lecture fees from AstraZeneca, Bayer, BMS, Eisai, Incyte, Ipsen, Merck Serono, Roche, Servier; travel expenses from AstraZeneca; research grants (to Institution) from Agios, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Zymeworks.LS: speakers\u2019 and consultant's fee from MSD, Astra-Zeneca, Servier, Bayer, Merck, Amgen, Pierre-Fabre, Takeda, GSKFP: reports personal fees from Amgen, Merck-Serono, MSD, Bayer, Astellas, Takeda, Servier, GlaxoSmithKline, Pierre-Fabre, Ipsen, J&J; and research grant (institutional) from Lilly, BMS, AstraZeneca, Incyte, Amgen, and Agenus.LF: reports personal honoraria as invited speaker from Incyte, Bristol Myers Squibb, Lilly; research funding (to Institution) from MSD, Bristol Myers Squibb, AstraZeneca, Incyte, BeiGene, Astellas, Daiichi Sankyo, Roche; participation in advisory board for MSD, AstraZeneca, Incyte, Taiho, Servier, Daiichi Sankyo, Lilly, Astellas.RIG: advisory fee da MSD ItaliaLS: speakers\u2019 and consultant's fee from MSD, Astra-Zeneca, Servier, Bayer, Merck, Amgen, Pierre-Fabre, Takeda, GSKRM: honoraria from BoeringerDM: Research Grants from Celgene, Evotec, Incyte, iOnctura, Roche, Servier, Shire; Consulting fees from Eli Lilly, Evotec, Incyte, iOnctura, IQVIA, Servier, Shire, Taiho; Honoraria for participation to Advisory Boards from Incyte, Roche, Servier, Taiho, Terumo; Payment for lectures or presentations from Baxter, Incyte, MSD Italia, Roche, ServierFdB: Consulting: BMS, Pierre Fabre, Mattioli 1885, MCCann Health, MSD, IQVIA, Novartis; Advisory arrangements: Tiziana Life Sciences, BMS, Celgene, Novartis, Servier, Pharm Research Associated, Daiichi Sankyo, Ignyta, Amgen, Pfizer, Octimet Oncology, Incyte, Pierre Fabre, Eli Lilly, Roche, AstraZeneca, Gentili, Dephaforum, Merck & Co., Kenilworth, NJ, Bayer, Fondazione Menarini, Sanofi, Incyte, Taiho; Speaker\u2019s fees from BMS, Roche, Merck & Co., Kenilworth, NJ, Bayer, Ignyta, Dephaforum, Biotechespert, Prime Oncology, Pfizer, Nadirex, Ambrosetti, Incyte, Motore Sanit\u00e0, Events, Fare Comunicazione, Itanet, Nadirex, ESO, AccMed, Idea-z; Grants\/contracts: research, unrestricted, and\/or travel: Novartis, Roche, BMS, Celgene, Incyte, NMS, the healthcare business of Merck KGaA, Darmstadt, Germany, Kymab, Pfizer, Tesaro, and Merck & Co., Kenilworth, NJ; Traveling expenses from Bristol Myers Squibb, Roche, Celgene, Amgen.All other authors declared no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"436"}}